display
A data analysis in Israel on the use of the Biontech / Pfizer vaccine against Corona certifies that the preparation is highly effective.
The health insurance company Clalit included 600,000 people whose second vaccination had been at least a week earlier.
According to a Clalit spokeswoman on Sunday, there were 94 percent fewer symptomatic infections in the group of those who had been vaccinated than in a control group of people who had not yet been vaccinated.
Those who became infected despite being vaccinated had 92 percent fewer severe courses.
Of the 600,000 people in each group, about 430,000 were between 16 and 59 years old, with the remainder 60 and older.
Another analysis had previously shown that people who become infected with the Sars-CoV-2 pathogen after a corona vaccination apparently reproduce fewer viruses than those who have not been vaccinated - and are therefore possibly less contagious.
This already applies after a single vaccination dose, Israeli researchers reported on the preliminary data.
Pfizer had given effectiveness with 95 percent
display
For Biontech / Pfizer, Israel is practically a model country.
In return for vaccine deliveries, the Israeli government provides the companies with data from the vaccination campaign.
Clalit expert Ran Balicer said after the extensive test it was now clear that the Biontech / Pfizer vaccine was highly effective one week after the second dose was administered.
The two companies had given the effectiveness of their preparation a week after the second dose with 95 percent.
An intensive vaccination campaign has been running in Israel since December 19.
According to the Ministry of Health on Monday, around 3.9 million citizens have received the first dose and around 2.5 million citizens have also received the second dose.
In total, the small country has a little over nine million inhabitants.
The government plans to offer vaccinations to all residents of the country who are older than 16 years by the end of March.